The event holds vital for a number of folks utilizing glasses, that as an alternative of placing on studying glasses at any time when small print turns into troublesome to see, a once-daily drop is meant to enhance close to imaginative and prescient for a part of the day.
Lupin, by means of its wholly owned subsidiary VISUfarma, has just lately secured unique rights to commercialise Yuvezzi, developed by Tenpoint Therapeutics, throughout the European Union, the UK, Switzerland, Norway and Iceland. Yuvezzi obtained US FDA approval in January 2026 and have become commercially obtainable within the US in March.
Yuvezzi is designed to work by quickly making it simpler for the attention to deal with close by objects. The impact shouldn’t be everlasting, and the product shouldn’t be meant to get rid of the necessity for studying glasses altogether.
Tenpoint’s scientific research assessed near-vision efficiency at intervals beginning half-hour after dosage and persevering with by means of eight hours. The corporate says the drop can present improved close to imaginative and prescient for as much as eight hours. Importantly, that doesn’t imply each affected person will get eight hours of glasses-free imaginative and prescient. The length and diploma of profit range, making the on a regular basis expertise of the therapy an vital a part of its industrial proposition.
The transfer provides to Lupin’s ophthalmology enterprise following its acquisition of VISUfarma in April 2026. VISUfarma introduced greater than 60 branded ophthalmology merchandise throughout dry eye, glaucoma, eyelid hygiene, blepharitis, retinal well being and specialised nutraceuticals, together with a industrial presence in Italy, the UK, Spain, Germany and France.
Vinita Gupta, CEO, Lupin, stated, “The acquisition of VISUfarma marks a big step in our technique to construct a differentiated world specialty enterprise and strengthen our presence in key European markets. Past increasing our ophthalmology footprint, VISUfarma offers us with a powerful industrial platform, a trusted portfolio of revolutionary eye-care manufacturers, and deeper entry to sufferers and healthcare professionals throughout Europe.”
The broader world presbyopia market was estimated at $10.66 billion in 2025 and is projected to succeed in $13.88 billion by 2030, in response to The Enterprise Analysis Firm. The estimate covers the broader presbyopia market and never prescription eye drops alone.
The US is offering early industrial proof. LENZ Therapeutics, which markets VIZZ, reported $1.7 million in product gross sales within the second quarter of 2026, taking first-half gross sales to $3.4 million. The corporate stated greater than 13,000 eye-care professionals had prescribed VIZZ by the tip of June, with about 75% having prescribed it greater than as soon as. Greater than 60% of sufferers utilizing its e-pharmacy channel had bought a couple of month-to-month pack.
Orasis Prescribed drugs, which markets Qlosi, reported a 49.1% refill fee 15 months after launch in July 2026. The repeat-purchase information is related as a result of the drops present momentary enchancment in close to imaginative and prescient and should be used usually.
That creates a unique proposition from studying glasses. Analysts stated that glasses are a one-time buy that can be utilized repeatedly, whereas prescription drops need to be administered every day to keep up the impact. For customers, subsequently, comfort needs to be weighed towards the fee, frequency of use, length of impact and any unwanted effects.
“Prescription eye drops for presbyopia have the potential to create a significant new pharmaceutical class, however I don’t see them changing studying glasses. The extra possible final result is coexistence the place glasses stay the cheap, dependable default, whereas drops create a sizeable comfort marketplace for sufferers who need a number of hours of spectacle-free close to imaginative and prescient,” stated Salil Kallianpur, pharma analyst.
Kallianpur stated adoption would rely much less on the novelty of a watch drop and extra on its on a regular basis worth to sufferers.
“The adoption will probably be decided much less by the novelty of a watch drop and extra by the on a regular basis shopper proposition comparable to does it work predictably, does it final by means of many of the working day, is it nicely tolerated, inexpensive and handy sufficient to make use of repeatedly and so on. Period and consistency will in all probability come first, adopted by value and comfort.”
For Lupin, Yuvezzi builds on the ophthalmology platform created by means of VISUfarma. Ramesh Swaminathan, Government Director, World CFO, Head of IT and API Plus SBU, Lupin, stated, “VISUfarma has considerably strengthened Lupin’s ophthalmology platform, bringing collectively a differentiated portfolio, established industrial capabilities, and a powerful presence throughout key European markets. The following addition of revolutionary therapies comparable to Yuvezzi additional validates the strategic rationale of the acquisition and enhances our skill to create sustained worth by means of specialty-led progress.”
In India, Entod Prescribed drugs has already introduced the prescription eye-drop method into the market with PresVu, a 1.25% pilocarpine hydrochloride formulation for grownup presbyopia. Medical analysis revealed within the Indian Journal of Ophthalmology has examined the efficacy and security of pilocarpine 1.25% in sufferers with presbyopia.
